Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells

ADAM17 is upregulated in many cancers and in turn activates signaling pathways, including EGFR/ErbB, as well as those underlying resistance to targeted anti-EGFR therapies. Due to its central role in oncogenic pathways and drug resistance mechanisms, specific and efficacious monoclonal antibodies ag...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nayanendu Saha, Kai Xu, Zhongyu Zhu, Dorothea Robev, Teja Kalidindi, Yan Xu, Juha Himanen, Elisa de Stanchina, Naga Vara Kishore Pillarsetty, Dimiter S Dimitrov, Dimitar B Nikolov
Format: article
Langue:EN
Publié: Elsevier 2022
Sujets:
Accès en ligne:https://doaj.org/article/0c1537a2f183403bbaf393d83c36b312
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!